Bioavailability of Rimactazid

  • R. L. Parsons
  • G. M. Hossack
  • P. F. G. Boon
  • D. M. Burley
Part of the Chemotherapy book series (CT, volume 3)


Rifampicin has now got an established place as a first line agent in the management of tuberculosis. Its advantages include proven efficacy(1), nausea is relatively infrequent (2), a low incidence of bacterial drug resistance (3) and the possibility of shortening the normally prolonged course of antituberculous chemotherapy.


Isonicotinic Acid Combine Figure Bacillus Brevis Combine Preparation Separate Preparation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. (1).
    Neuman, R., Doster, B., Murray, F.J. & Ferebee, (1971) Rifampicin in initial treatment of pulmonary tuberculosis. Amer. Rev. resp. Dis. 103, 461–476.Google Scholar
  2. (2).
    Mattson, K., (1972) Rifampicin induced side effects. Symposium on Rifampicin & current policies in antituberculous chemotherapy. Ciba Foundation, London.Google Scholar
  3. (3).
    Grumbach, F. & Rist, N. (1967) Experimental antituberculous activity of rifampicin, derivative of rifamycin SV. Rev. Tuberc. Pneumol. ( Paris ) 31, 749.Google Scholar
  4. (4).
    Boman, G. Borga, O., Hanngren, A. et. al. (1970) Pharmacokinetic interactions between the tuberculostatics rifampicin, para-aminosalicylic acid and isoniazid. Acta. Pharmac. Toxicol. 28, Suppi. 1, 15.Google Scholar
  5. (5).
    Acocella, G. (1971) A metabolic & kinetic study on the association rifampicinisoniazid. Respiration, 28, Suppl. 1–6.Google Scholar
  6. (6).
    Burley, D.M. (1972) Rifampicin, isoniazid & hepatotoxicity. Proceedings of the 258th meeting of the Danish Pneumological society. p. 25.Google Scholar
  7. (7).
    Grove, D.C. & Randall, W.A.(1955)Assay methods of antibiotics. A laboratory manual. Medical Encyclopedia. Inc., New York.Google Scholar
  8. (8).
    Burley, D.M. Personal communication.Google Scholar
  9. (9).
    Porven, G. & Canetti, G. (1968) Revue Tuberc. 32 (5) 707–716.Google Scholar
  10. (10).
    Gialdroni-Grassi, G. (1969) Some aspects of the antimycobacterial activity of rifampicin. Simposi Scientifici Lepetit 20, 51–57.Google Scholar
  11. (11).
    Ellard, G.A., Gammon, G.T. & Wallace, S.M. (1972) The determination of isoniazid and its metabolites acetylisoniazid, isonicotinic acid and isonicotinylglycine in serum and urine. Biochem. J. 126, 449–458.Google Scholar
  12. (12).
    Pallanza, R., Arioli, V., Furesz, S. et al. (1967) Rifampicin: a new rifamycin II. Laboratory studies on the antituberculous activity & preliminary clinical observations. Arzneimittel-Forsh, 17. 529–534.Google Scholar

Copyright information

© Plenum Press, New York 1976

Authors and Affiliations

  • R. L. Parsons
    • 1
  • G. M. Hossack
    • 1
  • P. F. G. Boon
    • 2
  • D. M. Burley
    • 2
  1. 1.Department of Clinical PharmacologyGuy’s Hospital Medical SchoolLondonUK
  2. 2.Ciba Laboratories, Ltd.Horsham. SussexUK

Personalised recommendations